{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacogenomics+Testing&page=2",
    "query": {
      "intervention": "Pharmacogenomics Testing",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacogenomics+Testing&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-16T23:15:49.991Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02399371",
      "title": "Pembrolizumab in Treating Patients With Malignant Mesothelioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Biphasic Mesothelioma",
        "Epithelioid Mesothelioma",
        "Peritoneal Malignant Mesothelioma",
        "Pleural Biphasic Mesothelioma",
        "Pleural Epithelioid Mesothelioma",
        "Pleural Malignant Mesothelioma",
        "Pleural Sarcomatoid Mesothelioma",
        "Recurrent Peritoneal Malignant Mesothelioma",
        "Recurrent Pleural Malignant Mesothelioma",
        "Sarcomatoid Mesothelioma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacogenomic Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2015-03-31",
      "completion_date": "2026-03-20",
      "has_results": true,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-09-16T23:15:49.991Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02399371"
    },
    {
      "nct_id": "NCT01705106",
      "title": "Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "celecoxib",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacogenomic studies",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2012-08-29",
      "completion_date": "2016-02-10",
      "has_results": true,
      "last_update_posted_date": "2018-05-30",
      "last_synced_at": "2026-09-16T23:15:49.991Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01705106"
    },
    {
      "nct_id": "NCT03579121",
      "title": "Genomic Opioid Optimization of Dosing and Selections (GOODS) Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Perioperative/Postoperative Complications"
      ],
      "interventions": [
        {
          "name": "Pharmacogenomic (PGx)",
          "type": "OTHER"
        },
        {
          "name": "Review results",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 76,
      "start_date": "2018-10-12",
      "completion_date": "2022-04-01",
      "has_results": false,
      "last_update_posted_date": "2022-06-15",
      "last_synced_at": "2026-09-16T23:15:49.991Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03579121"
    },
    {
      "nct_id": "NCT05346770",
      "title": "Pharmacist-led Interventions to Improve Medication Use",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pharmacogenomics",
        "Old Age"
      ],
      "interventions": [
        {
          "name": "Behavioral Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Diagnostic Test",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Data Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DIAGNOSTIC_TEST",
        "OTHER"
      ],
      "sponsor": "Tabula Rasa HealthCare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2022-01-25",
      "completion_date": "2024-07-24",
      "has_results": false,
      "last_update_posted_date": "2022-09-02",
      "last_synced_at": "2026-09-16T23:15:49.991Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05346770"
    },
    {
      "nct_id": "NCT01105663",
      "title": "Pharmacologic Impact on Sedation Assessments",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pediatric Acute Lung Injury"
      ],
      "interventions": [
        {
          "name": "Pharmacokinetic Sampling and pharmacogenetic analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 175,
      "start_date": "2010-03",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2017-01-27",
      "last_synced_at": "2026-09-16T23:15:49.991Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01105663"
    },
    {
      "nct_id": "NCT03216499",
      "title": "HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "HIF-2alpha Inhibitor PT2385",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacogenomic Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2017-09-14",
      "completion_date": "2020-06-05",
      "has_results": true,
      "last_update_posted_date": "2022-05-09",
      "last_synced_at": "2026-09-16T23:15:49.991Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03216499"
    },
    {
      "nct_id": "NCT00226577",
      "title": "Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2004-02",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2017-03-23",
      "last_synced_at": "2026-09-16T23:15:49.991Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00226577"
    },
    {
      "nct_id": "NCT00991081",
      "title": "Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Smoking"
      ],
      "interventions": [
        {
          "name": "Counseling",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Self-help guide",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Pharmacotherapy",
          "type": "DRUG"
        },
        {
          "name": "Genetic feedback, verbal",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Genetic feedback, printed",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2009-07",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2012-09-19",
      "last_synced_at": "2026-09-16T23:15:49.991Z",
      "location_count": 3,
      "location_summary": "Menlo Park, California • Stanford, California • Seattle, Washington",
      "locations": [
        {
          "city": "Menlo Park",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00991081"
    },
    {
      "nct_id": "NCT06322238",
      "title": "Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pharmacogenomic Drug Interaction",
        "Side Effect of Drug",
        "Ineffective Drug Action",
        "Drug Metabolism, Poor, CYP2D6-Related",
        "Drug Metabolism, Poor, CYP2C19-Related"
      ],
      "interventions": [
        {
          "name": "PGx panel test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2024-12-01",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-09-16T23:15:49.991Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06322238"
    },
    {
      "nct_id": "NCT01713972",
      "title": "Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "pazopanib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Correlative studies",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Manisha Shah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2012-11-19",
      "completion_date": "2018-12-26",
      "has_results": false,
      "last_update_posted_date": "2019-03-01",
      "last_synced_at": "2026-09-16T23:15:49.991Z",
      "location_count": 2,
      "location_summary": "Columbus, Ohio • Houston, Texas",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01713972"
    }
  ]
}